ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering

Slides:



Advertisements
Similar presentations
TALENs. Transcription activator-like effectors (TALEs) are produced by plant pathogenic bacteria in the genus Xanthomonas Target host cells via type III.
Advertisements

Cermak, Doyle, Christian, Wang, Zhang, Schmidt, Baller, Somia, Bogdanove, Voytas Nucleic Acids Research, March 24, 2011 Shelley Ackerman Journal.
The beginnings of gene editing
Genome Editing by Matthew Porteus Department of Pediatrics,
Genome editing to breed better plants
METHODS OF GENOME ENGINEERING: A NEW ERA OF MOLECULAR BIOLOGY
Pluripotent stem cell based gene therapy for hematological diseases
Rachel Wynberg, Sarah A. Laird  Trends in Biotechnology 
A Robust Network of Double-Strand Break Repair Pathways Governs Genome Integrity during C. elegans Development  Daphne B. Pontier, Marcel Tijsterman 
MSc Student Of Hematology
CRISPR-Cas Systems: Prokaryotes Upgrade to Adaptive Immunity
Genome-editing Technologies for Gene and Cell Therapy
Figure 2 Use of CRISPR/Cas9 for genome editing
Figure 3 Endogenous repair of double-strand DNA breaks
Looking forward to genetically edited fruit crops
Harnessing CRISPR–Cas systems for bacterial genome editing
Astrid Breitbart, Charles E. Murry  Cell Stem Cell 
CRISPR-Cas Systems: Prokaryotes Upgrade to Adaptive Immunity
Addison V. Wright, James K. Nuñez, Jennifer A. Doudna  Cell 
Research Techniques Made Simple: The Application of CRISPR-Cas9 and Genome Editing in Investigative Dermatology  Joan Ramon Guitart, Jodi L. Johnson,
Mouse Genome Engineering via CRISPR-Cas9 for Study of Immune Function
Luther Davis, Nancy Maizels  Cell Reports 
Feasibility of new breeding techniques for organic farming
Volume 7, Issue 1, Pages (April 2014)
Astrid Breitbart, Charles E. Murry  Cell Stem Cell 
Molecular Therapy - Nucleic Acids
Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR
CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles
Therapeutic editing of hepatocyte genome in vivo
USH2A Gene Editing Using the CRISPR System
Itai M. Pessach, MD, PhD, Luigi D. Notarangelo, MD 
CRISPR genome-editing: A medical revolution
Molecular Therapy - Nucleic Acids
Volume 154, Issue 6, Pages (September 2013)
Zinc Fingers, TAL Effectors, or Cas9-Based DNA Binding Proteins: What’s Best for Targeting Desired Genome Loci?  Annett Strauβ, Thomas Lahaye  Molecular.
Current Progress in Therapeutic Gene Editing for Monogenic Diseases
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
Genome-editing Technologies for Gene and Cell Therapy
Beth Elliott, Christine Richardson, Maria Jasin  Molecular Cell 
Advances in Industrial Biotechnology Using CRISPR-Cas Systems
DNA Double-Strand Breaks Come into Focus
Melissa S Jurica, Raymond J Monnat, Barry L Stoddard  Molecular Cell 
Translocation Mapping Exposes the Risky Lifestyle of B Cells
Genome Editing Technologies: Defining a Path to Clinic
Molecular Therapy - Methods & Clinical Development
A CRISPR Approach to Gene Targeting
Volume 23, Issue 1, Pages (January 2015)
William T. Hendriks, Curtis R. Warren, Chad A. Cowan  Cell Stem Cell 
Molecular Therapy - Nucleic Acids
Meigang Gu, Kanagalaghatta R. Rajashankar, Christopher D. Lima 
Ignazio Maggio, Manuel A.F.V. Gonçalves  Trends in Biotechnology 
Volume 14, Issue 4, Pages (April 2006)
Structure of the Staphylococcus aureus AgrA LytTR Domain Bound to DNA Reveals a Beta Fold with an Unusual Mode of Binding  David J. Sidote, Christopher.
Gene editing: modifying a gene that was already there
Gene editing by CRISPR/Cas9 for gene inactivation and targeted sequence replacement. Gene editing by CRISPR/Cas9 for gene inactivation and targeted sequence.
Molecular Therapy - Methods & Clinical Development
Jia Liu, Thomas Gaj, Mark C Wallen, Carlos F Barbas 
Are Mouse Telomeres Going to Pot?
Structural Basis of Proline-Proline Peptide Bond Specificity of the Metalloprotease Zmp1 Implicated in Motility of Clostridium difficile  Magdalena Schacherl,
Chemical Biology Approaches to Genome Editing: Understanding, Controlling, and Delivering Programmable Nucleases  Johnny H. Hu, Kevin M. Davis, David R.
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Nucleic Acids
Nuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off- target Effects in Genome Editing  Ciaran M Lee, Thomas J Cradick,
CRISPR in Parasitology: Not Exactly Cut and Dried!
Thomas Gaj, Benjamin E Epstein, David V Schaffer  Molecular Therapy 
Volume 19, Issue 4, Pages (April 2011)
Volume 9, Issue 4, Pages (April 2016)
New Tools for Genome Modification in Human Embryonic Stem Cells
CRISPR Craze to Transform Cardiac Biology
Engineering Globin Gene Expression
Presentation transcript:

ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering Thomas Gaj, Charles A. Gersbach, Carlos F. Barbas  Trends in Biotechnology  Volume 31, Issue 7, Pages 397-405 (July 2013) DOI: 10.1016/j.tibtech.2013.04.004 Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 1 Structure of zinc-finger and transcription activator-like effectors (TALEs). (A) (Top) Designed zinc-finger protein in complex with target DNA (grey) (PDB ID: 2I13). Each zinc-finger consists of approximately 30 amino acids in an ββα arrangement (inset). Surface residues (-1, 2, 3 and 6) that contact DNA are shown as sticks. Each zinc-finger domain contacts 3 or 4bp in the major groove of DNA. The side chains of the conserved Cys and His residues are depicted as sticks in complex with a Zn2+ ion (purple). (B) Cartoon of a zinc-finger nuclease (ZFN) dimer bound to DNA. ZFN target sites consist of two zinc-finger binding sites separated by a 5–7-bp spacer sequence recognized by the FokI cleavage domain. Zinc-finger proteins can be designed to recognize unique ‘left’ and ‘right’ half-sites. (C) (Top) TALE protein in complex with target DNA (grey) (PDB ID: 3UGM). Individual TALE repeats contain 33–35 amino acids that recognize a single base pair via two hypervariable residues (repeat-variable diresidues; RVDs) (shown as sticks) (inset). (D) Cartoon of a TALE nuclease (TALEN) dimer bound to DNA. TALEN target sites consist of two TALE binding sites separated by a spacer sequence of varying length (12–20bp). TALEs can be designed to recognize unique left and right half-sites. RVD compositions are indicated. Trends in Biotechnology 2013 31, 397-405DOI: (10.1016/j.tibtech.2013.04.004) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 2 Overview of possible genome editing outcomes using site-specific nucleases. Nuclease-induced DNA double-strand breaks (DSBs) can be repaired by homology-directed repair (HDR) or error-prone nonhomologous end joining (NHEJ). (A) In the presence of donor plasmid with extended homology arms, HDR can lead to the introduction of single or multiple transgenes to correct or replace existing genes. (B) In the absence of donor plasmid, NHEJ-mediated repair yields small insertion or deletion mutations at the target that cause gene disruption. In the presence of double-stranded oligonucleotides or in vivo linearized donor plasmid, DNA fragments up to 14kb have been inserted via NHEJ-mediated ligation. Simultaneous induction of two DSBs can lead to deletions, inversions and translocations of the intervening segment. Trends in Biotechnology 2013 31, 397-405DOI: (10.1016/j.tibtech.2013.04.004) Copyright © 2013 Elsevier Ltd Terms and Conditions